-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Recent News from ILCN
-
In Brief: July 23, 2025
The US FDA grants Orphan Drug Designation to CID-078 for SCLC, and zidesamtinib demonstrates positive early data in ROS1-positive NSCLC.
-
SACHI Trial Results: Savolitinib-Osimertinib Combo Improves PFS in MET-Amplified EGFR-Mutated NSCLC
Dr. Shun Lu said savolitinib plus osimertinib offers a potential new chemo-free treatment option for patients after progression on first-line treatment.
-
IMpower010 Trial Update Highlights Long-Term Benefits of Adjuvant Atezolizumab in Resected NSCLC
The updated data and a recently presented exploratory analysis show the benefits varied based on PD-L1 expression, which may be influenced by a variety of genomic alterations.
-
Bispecific T-cell Engagers: Understanding the Evolving and Innovative Approaches to Outpatient Side Effect Management
Dr. Melissa L. Johnson discusses evolving best practices for the operationalization of bispecific T-cell engagers, specifically tarlatamb.
-
IASLC Committee Spotlight: Multidisciplinary Clinical Science Committee
Dr. Tom Stinchcombe discusses how this new IASLC committee is aiming to define multidisciplinary care, improve global access, and support collaborative science.
-
In Brief for July 9, 2025
The FDA grants accelerated approval to Dato-DXd, while a Biologics License Application for HER3-DXd is voluntarily withdrawn.
-
Tarlatamab Emerges as New Standard of Care in Second-Line SCLC, with Significant Gains in OS, PFS
Dr. Charles M. Rudin, who presented data from the DeLLphi-304 trial at ASCO 2025, noted that patient-reported outcomes also showed improvements in common symptoms, including dyspnea and cough, with fewer toxicities of grade 3 or higher.
-
A Paradigm Shift: Final 5-Year Overall Survival Results from CheckMate 816 in Resectable NSCLC
Dr. Patrick Forde recently presented milestone data from the trial that confirms the benefit of neoadjuvant-only chemoimmunotherapy for the treatment of resectable lung cancer.
-
Patient Perspective: Copay Accumulators Create Yet Another Cost Burden Faced by US Patients in Treatment with Targeted Therapies
Advocate and best-selling author Annabelle Gurwitch shines light on pharmacy benefit practices that cost patients thousands while increasing profits for insurance companies.
-
Research to Watch: FDA Grants ZL-1310 Fast Track Designation for Extensive-Stage SCLC
ZL-1310 earns Fast Track Designation as a potential first-in-class DLL3-targeted ADC for extensive-stage small cell lung cancer.